Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Black Diamond Therapeutics, a clinical-stage oncology company, will host a webcast on May 21, 2026, to present updated results from its ongoing Phase 2 trial of Silevertinib in frontline patients with EGFR-mutated non-small cell lung cancer. The company focuses on developing MasterKey therapies that target oncogenic mutations, aiming to overcome re…